Aspirin resistance and compliance with therapy.

abstract：BACKGROUND:Levosimendan is a noncatecholamine inotrope that does not increase oxygen consumption, utilized for the treatment for acute heart failure with left ventricular (LV) systolic dysfunction. Its use in takotsubo cardiomyopathy (TTC), a disease that contraindicates the use of catecholamine inotropes, is not well ...

journal_title：Cardiovascular therapeutics

authors： Santoro F,Ieva R,Ferraretti A,Ienco V,Carpagnano G,Lodispoto M,Di Biase L,Di Biase M,Brunetti ND

更新日期：2013-12-01 00:00:00

abstract：AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...

journal_title：Cardiovascular therapeutics

authors： Slettom G,Jonassen AK,Breivik L,Seifert R,Nordrehaug JE

更新日期：2013-12-01 00:00:00

abstract：Background:Atherosclerosis (AS) is a common severe disease around the world. The merging paper reported that long noncoding RNAs (lncRNAs) took part in diversified pathological processes of AS, although the mechanism remains unknown. This study is aimed at uncovering the profile of lncRNA taurine-upregulated gene 1 (TU...

journal_title：Cardiovascular therapeutics

authors： Tang Y,Hu J,Zhong Z,Liu Y,Wang Y

更新日期：2020-05-29 00:00:00

abstract：:In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

journal_title：Cardiovascular therapeutics

authors： Perin EC,Silva GV

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...

journal_title：Cardiovascular therapeutics

authors： Kloner RA,Dow JS,Bhandari A

更新日期：2011-08-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease is a major cause of death worldwide. Different medical and surgical therapeutic options are well established, but a significant number of patients are not amenable to standard therapeutic options. Cell-based therapies after clinical application have shown different results in recent ...

journal_title：Cardiovascular therapeutics

authors： Ghodsizad A,Ruhparwar A,Bordel V,Mirsaidighazi E,Klein HM,Koerner MM,Karck M,El-Banayosy A

更新日期：2013-12-01 00:00:00

abstract：:The pericardium is composed of visceral and parietal components. In view of the pericardium's simple structure, pathologic processes involving it are understandably few. However, despite a limited number of clinical syndromes, the pericardium is affected by virtually every category of disease, including infectious, ne...

journal_title：Cardiovascular therapeutics

authors： Azam S,Hoit BD

更新日期：2011-10-01 00:00:00

abstract：:Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...

journal_title：Cardiovascular therapeutics

authors： Romero I,Nedios S,Kriatselis C

更新日期：2014-10-01 00:00:00

abstract：AIMS:We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. METHODS:Sixty healthy subjects (39 male, 21 female; age 20-45 years) were randomized to receive a single subcu...

journal_title：Cardiovascular therapeutics

authors： Lunven C,Paehler T,Poitiers F,Brunet A,Rey J,Hanotin C,Sasiela WJ

更新日期：2014-12-01 00:00:00

abstract：AIM:Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS:A complete community-based heart failure population was studied. ...

journal_title：Cardiovascular therapeutics

authors： Jonsson A,Norberg H,Bergdahl E,Lindmark K

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...

journal_title：Cardiovascular therapeutics

authors： Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

journal_title：Cardiovascular therapeutics

authors： Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

更新日期：2017-10-01 00:00:00

abstract：AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

journal_title：Cardiovascular therapeutics

authors： Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

更新日期：2018-06-01 00:00:00

abstract：Objective:The drug efficacy may differ among different statins, and evidence from head-to-head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid-lowering/increasing effects of 7 different statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus by conducting s...

journal_title：Cardiovascular therapeutics

authors： Zhang X,Xing L,Jia X,Pang X,Xiang Q,Zhao X,Ma L,Liu Z,Hu K,Wang Z,Cui Y

更新日期：2020-04-23 00:00:00

abstract：Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

journal_title：Cardiovascular therapeutics

authors： Sunjaya AF,Sunjaya AP

更新日期：2019-04-01 00:00:00

abstract：:Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

journal_title：Cardiovascular therapeutics

authors： Escobar C,Barrios V,Jimenez D

更新日期：2010-10-01 00:00:00

abstract：AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

journal_title：Cardiovascular therapeutics

authors： Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

journal_title：Cardiovascular therapeutics

authors： Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

更新日期：2018-12-01 00:00:00

abstract：:Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart fr...

journal_title：Cardiovascular therapeutics

authors： Mohan M,McSwiggan S,Baig F,Rutherford L,Lang CC

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...

journal_title：Cardiovascular therapeutics

authors： Bocchi EA,Moura LZ,Issa VS,Cruz F,Carvalho VO,Guimarães GV

更新日期：2013-04-01 00:00:00

abstract：INTRODUCTION:Platelet activation participates in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear. AIMS:This study was designed to test MPs from healthy subject...

journal_title：Cardiovascular therapeutics

authors： Cheng G,Shan XF,Wang XL,Dong WW,Li Z,Liu XH,Zhang W,Xing K,Chang FJ

更新日期：2017-08-01 00:00:00

abstract：AIMS:Bariatric surgery has emerged as a promising treatment option for weight loss and to counter the metabolic consequences of obesity. Obesity has been linked to a hyperaggregable state, as well as a blunted response to aspirin. This pilot study assessed the hypothesis that bariatric surgery would lead to an improvem...

journal_title：Cardiovascular therapeutics

authors： Norgard NB,Monte SV,Fernandez SF,Ma Q

更新日期：2017-08-01 00:00:00

abstract：:Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury...

journal_title：Cardiovascular therapeutics

authors： Jang YH,Kim JH,Ban C,Ahn K,Cheong JH,Kim HH,Kim JS,Park YH,Kim J,Chun KJ,Lee GH,Kim M,Kim C,Xu Z

更新日期：2012-10-01 00:00:00

abstract：AIM:To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS:A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared a...

journal_title：Cardiovascular therapeutics

authors： Zhang J,Tian L,Huang J,Huang S,Chai T,Shen J

更新日期：2017-02-01 00:00:00

abstract：:There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

journal_title：Cardiovascular therapeutics

authors： Wong AK,AlZadjali MA,Choy AM,Lang CC

更新日期：2008-10-01 00:00:00

abstract：AIM:Cardiac hypertrophy and myocardial fibrosis significantly contribute to the pathogenesis of diabetic cardiomyopathy (DCM). Altered expression of several genes and their regulation by microRNAs has been reported in hypertrophied failing hearts. This study aims to examine the role of Cdc42, Pak1, and miR-30c in the p...

journal_title：Cardiovascular therapeutics

authors： Raut SK,Kumar A,Singh GB,Nahar U,Sharma V,Mittal A,Sharma R,Khullar M

更新日期：2015-06-01 00:00:00

abstract：INTRODUCTION:The metabolic modulator trimetazidine (TMZ) has been suggested to induce a metabolic shift from myocardial fatty acid oxidation (FAO) to glucose utilization, but this mechanism remains unproven in humans. The oxidation of plasma derived FA is commonly measured in humans, whereas the contribution of FA from...

journal_title：Cardiovascular therapeutics

authors： Bucci M,Borra R,Någren K,Pärkkä JP,Del Ry S,Maggio R,Tuunanen H,Viljanen T,Cabiati M,Rigazio S,Taittonen M,Pagotto U,Parkkola R,Opie LH,Nuutila P,Knuuti J,Iozzo P

更新日期：2012-12-01 00:00:00

abstract：OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to t...

journal_title：Cardiovascular therapeutics

authors： Ueda S,Yamagishi S,Matsui T,Noda Y,Ueda S,Jinnouchi Y,Sasaki K,Takeuchi M,Imaizumi T

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requiring aspirin therapy for secondary cardiovascular disease (CVD...

journal_title：Cardiovascular therapeutics

authors： Goldstein JL,Whellan DJ,Scheiman JM,Cryer BL,Eisen GM,Lanas A,Fort JG

更新日期：2016-04-01 00:00:00

abstract：Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

journal_title：Cardiovascular therapeutics

authors： Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

更新日期：2021-01-13 00:00:00